0
0
0
0
1
2
3
$0
Is West Pharmaceutical Services solid or fragile? The Finex Financial Health Scanner reads WST's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2025) | $3.1B |
|---|---|
| Net income | $493.7M |
| Operating margin | 19.0% |
| Net margin | 16.1% |
| Cash and investments | $791.3M |
| Total debt | $202.8M |
| Free cash flow | $345.6M |
| Revenue growth (1 year) | 6.3% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.